search
This update covers the Alliance Foundation Trial-46 (AFT-46), a study combining chemotherapy and immune checkpoint inhibitors for operable Stage 3A/B Non-Small Cell Lung Cancer (NSCLC). The presentation highlights the importance of mediastinal lymph node dissection for N2 nodal clearance. With 18 patients enrolled across 13 sites since March 2021, the trial shows promising responses after chemo and immunotherapy. The speaker explores future ideas, including preoperative chemo-immunotherapy, alternative biomarker studies, and a proposed AFT-51 trial focusing on metastasectomy with enhanced lesion detection using molecular imaging. The overall aim is to optimize surgical strategies for Stage 3 NSCLC, building on encouraging results from recent trials.
